US Patent 4,837,223: Scope, Claim Construction, and US Landscape for (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide
What does US 4,837,223 claim, in plain claim-scope terms?
US 4,837,223 is a US drug-composition and preparation-process patent focused on one stereoisomer: (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide, including (i) pharmaceutical compositions that are substantially free of the (R) isomer, and (ii) an associated process for preparing the (S) isomer by cyclization under specified conditions.
Based on the claim text provided:
Claim 1 (composition)
A pharmaceutical composition comprising:
- a therapeutically effective amount of (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide; and
- a pharmaceutically acceptable solid or liquid diluent/carrier; and
- the composition is substantially free of (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide.
Core scope elements in Claim 1
- Product type: pharmaceutical composition (drug product formulation).
- Active ingredient: (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide.
- Delivery matrix: any pharmaceutically acceptable solid or liquid carrier/diluent.
- Stereochemical purity requirement: “substantially free” of the (R) isomer.
Claim 2 (process and its stereochemical linkage)
Claim 2 depends on Claim 1’s identity of (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide and adds process limits and starting-material structure rules. It covers preparation of the (S) compound via cyclizing a specified (S)-2-amino-butanamide derivative.
Core scope elements in Claim 2
- Product identity: (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide, again “substantially free” of the (R) isomer.
- Process: cyclization in an inert solvent and in the presence of a basic substance.
- Substrate: an (S)-2-amino-butanamide of formula:
X--CH2CH2--Y--NHCH(C2H5)CONH2
- Substituent rules:
- X is either ZOO C-- or HalCH2 --
- Z is alkyl with 1 to 4 carbon atoms
- Hal is a halogen atom
- Y is either --CH2 -- or --CO--
- and the “with the proviso” rule ties X to Y:
- Y is --CH2 -- when X is ZOOC--
- Y is --CO-- when X is HalCH2 --
In effect, Claim 2 is a constrained process claim: it is not a broad “make the (S) isomer by any method.” It narrows to a particular cyclization logic using specific (S)-2-amino-butanamide precursors and particular substitution pairing.
How broad is the formulation claim versus the process claim?
The two claims operate on different axes of scope.
Claim 1 breadth drivers
- Carrier/diluent is unrestricted: “pharmaceutically acceptable solid or liquid diluent or carrier therefor” reads as open-ended.
- Active dosage is not numerically constrained: only “therapeutically effective amount.”
- Stereochemical purity is the principal limiting element: “substantially free” of (R).
Practical implication
- If a competitor markets a drug product containing the (S) isomer with only low (R) impurity, they can still land inside Claim 1 if “substantially free” is interpreted to cover the competitor’s residual (R) level.
Claim 2 breadth drivers
- Process is narrowed by:
- cyclization
- inert solvent
- presence of a basic substance
- and specific substrate structural requirements including X/Y pairing and Z carbon count.
- It also requires the resulting (S) product to be “substantially free” of (R), tying process to stereochemical outcome.
Practical implication
- A different synthetic route to (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide that avoids the claimed substrate patterns and/or the claimed cyclization conditions can fall outside Claim 2 even if it yields a similar purity (S) product.
What exactly is “substantially free of (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide”?
The phrase appears in both claims. As drafted, it is a relative purity limitation, not a numerical one.
Claim-scope consequences
- Patent infringement risk remains for formulations where the (R) content is reduced but not characterized as “zero.”
- Enforcement hinges on definition of “substantially free” in the patent’s specification (if numeric ranges or test methods exist) and how courts construe the term based on intrinsic evidence.
Because Claim 1 and Claim 2 both use the same limitation, a purity definition applies across product and process contexts.
How to interpret the substrate formula limits in Claim 2?
Claim 2’s substrate restriction is the tightest part of the process claim.
Substrate structural constraints
Claim 2 starts from an (S)-2-amino-butanamide with the general architecture:
X--CH2CH2--Y--NHCH(C2H5)CONH2
-
X options:
- ZOO C--
- Z = alkyl with 1 to 4 carbon atoms
- reads like an ester-type substituent (alkoxy carbonyl).
- HalCH2 --
- Hal = halogen atom (e.g., Cl/Br/I in practice).
-
Y options:
-
proviso tying X to Y:
- If X = ZOOC--, then Y = --CH2 --
- If X = HalCH2 --, then Y = --CO--
Tight pairing effect
This pairing makes Claim 2 narrower than a generic “cyclize an amino-butanamide.” A process that cyclizes a substrate where X and Y are mismatched to the proviso can avoid literal coverage.
Where is the likely litigation battleground: Claim 1 “substantially free” or Claim 2 structural pairing?
For freedom-to-operate and competitive diligence, the practical risk split is usually:
- Claim 1: purity and product composition.
- Claim 2: whether the competitor’s synthetic route matches the claimed substrate pattern and cyclization conditions.
Because Claim 1 covers any pharmaceutically acceptable carrier, it is typically harder to design around by formulation changes. If the active stereoisomer purity is in range, a composition launch can still fall inside the claim.
US patent landscape: what this patent likely covers in the broader (S)/(R) stereoisomer space
With only the two claim texts provided, the landscape can be mapped at the level of claim-family themes rather than named assignees or prosecution histories (which require bibliographic and document retrieval not provided here). The landscape described below is therefore framed as claim-scope and design-around logic that commonly clusters around stereoisomer-specific drug patents like this one.
Likely neighboring US patent categories around 4,837,223
- Stereoisomer composition claims
- compositions containing (S) isomer substantially free of (R)
- possibly with different carrier systems or dosage forms
- Process claims for making (S) isomer
- specific cyclization steps
- specific starting materials and reagent sets
- stereochemical controls (e.g., asymmetric introduction or chiral resolution leading to S-rich product)
- Intermediate and precursor patents
- precursors to the lactam core (or to cyclization substrates)
- specific (S)-2-amino-butanamide derivatives
- Analytical and specification-dependent claims
- sometimes separate patents cover chiral HPLC methods or criteria for “substantially free,” though that depends on whether the family elected to claim analytical methodology.
How competitors design around a claim set like this
Typical escape routes relative to the limitations visible in Claim 1 and Claim 2:
Design around Claim 1 (composition)
- Use a different active (not covered by the claim’s active ingredient identity).
- Control the residual (R) level so the product is not “substantially free” (but this typically makes the product less desirable pharmaceutically).
- Re-frame the composition so it is not a “pharmaceutical composition” in the claim sense (e.g., non-therapeutic research use). This is usually not a viable commercial strategy for a drug.
Design around Claim 2 (process)
- Use a different precursor that violates the X/Y pairing in the substrate formula.
- Use a different solvent system that fails the “inert solvent” constraint.
- Avoid base-catalyzed conditions that fail “in the presence of a basic substance.”
- Create the (S) isomer via a different synthetic logic (e.g., different ring-closure or stereochemical induction step) such that the cyclization is not performed as claimed.
Claim-by-claim infringement map (product vs manufacturing)
Claim 1 infringement triggers
A party is exposed if it:
- makes, uses, offers for sale, sells, or imports a pharmaceutical composition containing:
- (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide in a therapeutically effective amount, and
- a pharmaceutically acceptable solid/liquid carrier/diluent, and
- the composition is substantially free of the (R) isomer.
Claim 2 infringement triggers
A party is exposed if it:
- prepares (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide substantially free of (R), using:
- a cyclization in an inert solvent with a basic substance, starting from an (S)-2-amino-butanamide with the claimed X--CH2CH2--Y--NHCH(C2H5)CONH2 structural constraints and proviso pairing.
Scope summary: what is clearly included
- Any solid or liquid formulation with the (S) active and low (R) content.
- Process embodiments that use the claimed type of (S)-2-amino-butanamide cyclization with:
- inert solvent,
- base,
- and the X/Y pairing rule.
Scope summary: what is clearly excluded by the visible claim language
- Formulations not containing the (S) active (or not containing a therapeutically effective amount).
- Formulations that are not “pharmaceutically acceptable” carriers/diluents.
- Processes that do not use:
- the claimed cyclization framework,
- an inert solvent,
- a basic substance,
- or that start from substrates that do not satisfy the X/Y proviso.
Key risk metrics for diligence (actionable)
The claims’ visible language points diligence to three technical checkpoints:
| Checkpoint |
Claim(s) |
Why it matters |
| Residual (R) impurity level and whether product is “substantially free” |
1, 2 |
Determines whether composition or product outcome fits the stereo purity limitation |
| Synthetic route mapping to the specific cyclization conditions (inert solvent + basic substance) |
2 |
Determines literal process coverage |
| Substrate identity and the X/Y proviso pairing |
2 |
Determines whether the starting material meets formula and pairing requirements |
Key Takeaways
- US 4,837,223 is centered on stereochemical selectivity: it protects pharmaceutical compositions containing (S)-α-ethyl-2-oxo-1-pyrrolidineacetamide with (R) substantially absent.
- Claim 1 is broad on formulation (any solid or liquid pharmaceutically acceptable carrier/diluent) and narrow mainly on active identity and stereo purity.
- Claim 2 is narrower on process: it ties cyclization to inert solvent + basic conditions and requires a specific (S)-2-amino-butanamide substrate structure with an X/Y proviso pairing.
- In freedom-to-operate work, the highest leverage points are residual (R) quantification (for Claim 1) and substrate/cyclization condition mapping (for Claim 2).
FAQs
1) Does Claim 1 require a specific dosage form?
No. It requires a pharmaceutical composition with a therapeutically effective amount and a pharmaceutically acceptable solid or liquid carrier/diluent. Dosage form is not limited in the provided claim text.
2) Can a formulation still infringe if it contains trace (R) isomer?
Yes, if the trace amount still satisfies the claim’s “substantially free” limitation. The limitation is not numerically stated in the claim text provided.
3) Is Claim 2 limited to only one cyclization solvent system?
Yes. It requires cyclization in “an inert solvent” and with a “basic substance.” Processes that use non-inert solvents or avoid basic conditions are more likely to fall outside Claim 2.
4) Does Claim 2 cover any way of making the (S) isomer?
No. It is limited to cyclizing the specified (S)-2-amino-butanamide structure with the X/Y proviso pairing.
5) What is the design-around path with the least formulation effort?
Reformulation alone is unlikely to avoid Claim 1 because the carrier is broadly defined. The more effective lever is typically controlling the (R) impurity level and/or changing manufacturing route to avoid Claim 2’s substrate/condition constraints.
References
[1] US Patent 4,837,223, claims 1-2 (provided claim text).
